Are vulvo-vaginal skin boosters different from fillers for dryness?
Yes—skin boosters and fillers are not the same. Skin boosters (e.g., hyaluronic-acid or polynucleotide injectables) aim to hydrate and condition tissue, potentially easing friction in genitourinary syndrome of menopause (GSM). Fillers are designed to add structure/volume and are not first-line for dryness. Foundations—vaginal moisturisers, suitable lubricants, and when needed, local oestrogen or DHEA—remain the mainstay; injectables are optional adjuncts after assessment. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Are vulvo-vaginal skin boosters different from fillers for dryness? Yes. While both are injectables, their goals differ. Skin boosters (such as non-crosslinked hyaluronic acid or polynucleotides) are formulated to improve tissue hydration and elasticity rather than to create bulk. They disperse through superficial planes, attract water and may support a smoother surface, which can help day-to-day comfort and reduce friction-related stinging in genitourinary syndrome of menopause (GSM)—also called vaginal atrophy. By contrast, fillers (typically crosslinked hyaluronic-acid gels) are designed to restore structure or contour in deeper planes (for example, aesthetic vulval volume), not to treat mucosal dryness itself.
Where these fit among first-line options. GSM stems from low oestrogen—the vaginal epithelium thins, pH rises, protective Lactobacillus declines and natural lubrication reduces. Guideline-led care in the UK starts with non-hormonal measures: a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) several times weekly for baseline hydration, plus a compatible personal lubricant for higher-friction moments (water-based for versatility/condoms; silicone-based for long glide when the vestibule is tender; oil-based feels rich but may degrade latex condoms/toys). If soreness, dyspareunia or micro-tears persist, local vaginal oestrogen or vaginal DHEA is usually the next step because these directly address the low-oestrogen biology.
Skin boosters vs fillers—how they behave in intimate tissue. 1) Depth and purpose: boosters are placed superficially to condition the mucosa/dermis-like layers; fillers are placed deeper to provide shape/structure. 2) Hydration vs volume: boosters prioritise water-binding and tissue quality; fillers prioritise projection and support. 3) Comfort impact: for penetration pain focused at the entrance (vestibule/posterior fourchette), a properly placed skin booster may reduce the “paper-cut” feel by improving slip; a filler will not usually solve GSM dryness and may increase pressure if placed in the wrong plane. 4) Combination care: best outcomes still depend on daily foundations and, when acceptable, local hormones—the injectables are adjuncts, not replacements.
Technique and placement matter more than brand. If your pain is entrance-focused, any local therapy must reach the vestibule; internal-only methods often miss the sore spot. The same principle applies to injectables: targeted, shallow placement at symptomatic areas matters, alongside a liberal, compatible lubricant during any higher-friction activity. Because evidence for boosters/polynucleotides is still emerging, we treat them as optional additions for selected patients who remain uncomfortable despite diligent basics ± local therapy, or for those who prefer to avoid hormones.
Safety and regulation in the UK. Products/devices should be UKCA/CE-marked for their intended use and used by trained clinicians with clear consent and aftercare. Expected short-lived effects include tenderness, pinpoint bruising or spotting. Red flags—fever, malodorous green/grey discharge, heavy bleeding, severe pelvic pain, visible blood in urine, or new post-menopausal bleeding—need prompt review. If you have fish allergy, check polynucleotide sourcing (some are salmon-derived). Avoid procedures if you have an active BV/thrush/UTI, unexplained bleeding, or recent pelvic surgery without clearance.
To see what treatment involves and how we sequence steps alongside moisturisers, local hormones and device options (e.g., radiofrequency/laser), review our clinic pathway pages. These explain how we minimise friction triggers, position local therapies, and consider adjuncts like boosters or polynucleotides only after the evidence-backed basics are in place.
Bottom line. Use skin boosters (or polynucleotides) only as adjuncts when GSM foundations and, if suitable, local hormones have been optimised. Fillers are for structure/shape and are not a treatment for dryness. Decisions are personalised and reviewed at 6–12 weeks to confirm benefit and settle on the lowest effective maintenance.
Clinical Context
Who might consider a skin booster? People with GSM whose main issue is entrance-focused stinging, micro-tears or friction during intimacy/walking despite a solid routine of moisturiser and a compatible lubricant—especially if local oestrogen/DHEA is unsuitable or only partly effective. Expect gradual change over weeks; plan review at 6–12 weeks.
Who should avoid or delay injectables now? Anyone with active thrush/BV/UTI, malodorous discharge, fever, severe pelvic pain, new post-menopausal bleeding, or recent pelvic/perineal surgery without clearance. If penetration pain is driven by pelvic floor guarding, start with pelvic health physiotherapy and, where helpful, graded dilator work; injectables cannot relax muscles.
Alternatives and next steps. Keep washing gentle (lukewarm water; bland emollient as a soap substitute); choose breathable underwear; change out of sweaty kit promptly; and avoid fragranced products. If dryness persists, optimise local oestrogen placement (including fingertip to the vestibule) or consider vaginal DHEA. Skin boosters/polynucleotides may be explored as add-ons after informed discussion of benefits, limits and costs. Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Guidelines & patient resources (UK): First-line GSM care emphasises vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life—see the NICE Menopause Guideline (NG23) and the NHS overview of vaginal dryness.
Comparators with stronger evidence: Cochrane reviews show that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings (see the Cochrane Library).
Moisturiser data: Clinical studies suggest hyaluronic-acid vaginal gels can improve GSM symptoms compared with baseline and, in some trials, comparably to low-dose oestrogen for selected outcomes; see peer-reviewed summaries on PubMed (public abstracts).
Regulation and safety: Device/product oversight and vigilance in the UK are outlined by the national regulator (medical devices); see the MHRA medical devices pages for intended-use and safety reporting principles.
Putting it together: Start with foundations → add local therapy if needed → consider skin boosters/polynucleotides only as adjuncts with clear consent and follow-up. ® belongs to its owner.